Ann Arbor biotech testing osteoporosis drug

Henderson, Tom
March 2008
Crain's Detroit Business;3/10/2008, Vol. 24 Issue 10, p25
The article offers information regarding the drug trials of VEL0230, being conducted by Velcura Therapeutics Inc. It states that Velcura, an Ann Arbor, Michigan-based biotech heavily funded by federal and state grants since it was founded in 2001, has begun clinical trials of a new drug to fight osteoporosis that it hopes will lead to its first round of venture-capital funding. INSET: STARTUPS WITH PFIZER ROOTS:.


Related Articles

  • $1 million-$5 million. Henderson, Tom // Crain's Detroit Business;11/24/2008, Vol. 24 Issue 47, p9 

    The article reports on Michael Long, founder, president and CEO of Ann Arbor-based Velcura Therapeutics Inc., who won the Crain's Small Business Award for enterpreneurship. Long is a former professor in the department of pediatrics at University of Michigan, where he filed a patent on forming...

  • Drug Trials and Older People. Witham, Miles D. // Drugs & Aging;2011, Vol. 28 Issue 8, p679 

    No abstract available.

  • From the Editor's desk. Tyrer, Peter // British Journal of Psychiatry;Mar2010, Vol. 196 Issue 3, p254 

    An introduction to the journal is presented in which the editor discusses reports published within the issue including the importance of attention to methodology in clinical trials, restriction of publication bias to drug trials, and the mental ill-effects of neglect, abuse, and deprivation.

  • National Pharmaceutical Institute answers allegations.  // Life Science Today;Feb2001, Vol. 2 Issue 1, p7 

    Reports on the Hungarian National Pharmaceutical Institute's denial that dangerous drug experiments are being carried out on unsuspecting patients. Rules concerning clinical trials in Hungary; Reasons that make Europe an easier place to find clinical trial patients.

  • ADVANCE-2: Apixaban had favorable risk-benefit profile compared with enoxaparin.  // Hem/Onc Today;8/10/2009, Vol. 10 Issue 15, p23 

    The article discusses the results of a clinical drug trial which revealed the therapeutic use of apixaban for thromboprophylaxis after total knee replacement.

  • New rules for industry-sponsored articles.  // Drug Utilization Review;Oct2001, Vol. 17 Issue 10, p77 

    Discusses the rules for drug industry-sponsored articles on clinical trials enforced by the joint editorial of 12 medical journals. Reasons for implementing the rules; Details of the rules; Journals that participated in the effort.

  • Clinical trials not to be taken lightly. White, Phil // New Zealand Doctor;10/8/2008, p13 

    The author expresses his view regarding phase 3 and 4 drug trials in New Zealand, which are being promoted as a business opportunity for general practice. According to the author, these trials should not be seen as low risk as it is the first opportunity to test the drugs on humans, and it...

  • Trial Scorecards.  // Cardiology Today;Sep2013, Vol. 16 Issue 9, p12 

    This section presents a summary of the results of several clinical trials involving cardiovascular drugs, as of September 2013, including the efficacy of apixaban for treatment of thrombosis and the treatment of chronic ischemic myocardium with combined extraporporeal shock wave therapy and...

  • Testing Products in China.  // Pharmaceutical Executive;May2002, Vol. 22 Issue 5, p20 

    Reports on the move of U.S. pharmaceutical companies towards testing products in China. Factors that make Chinese research trials relatively easy and affordable; Information on some companies that conducted trials in the country; Characteristics of drug testing in China.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics